An object of the present invention is to provide a method of producing a cell population comprising mesenchymal stem cells, comprising efficiently isolating a cell population comprising mesenchymal stem cells at high purity from an amnion. Provided is a method of producing a cell population comprising amnion-derived mesenchymal stem cells, comprising (1) storing an amnion in a medium for 4 hours or longer at 1 C. or higher and 25 C. or lower, followed by (2) isolating the amnion from the medium and treating the amnion with an enzyme; and (3) culturing a cell fraction comprising mesenchymal stem cells after the treatment with the enzyme.

The present invention relates to an epithelial stem/progenitor cell population isolated from the amniotic membrane of umbilical cord, the epithelial stem/progenitor cell population having the capacity to differentiate in multiple cell types. The invention also relates to a pharmaceutical composition comprising such an epithelial stem/progenitor cell population or a cellular extract thereof.

A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating a population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells.

The present disclosure relates to stem cells derived from a pure chorionic trophoblast layer (chorionic trophoblast layer without villi, CT-V), which is a part of the tissues of the placenta, and cell therapy comprising same. Stem cells derived from a pure chorionic trophoblast layer according to the present invention exhibit uniform growth characteristic, and superb proliferation and differentiation characteristics compared to the conventional stem cells derived from the whole placenta, and particularly, exhibit excellent differentiation into cartilage cells, thus can be effectively used in cell therapy for treating cartilage damage, deficiency and such, and as a composition for tissue regeneration.

Provided are a method of preparing a stem cell-derived epidermal progenitor cell conditioned medium, the method including: differentiating stem cells to stem cell-derived epidermal progenitor cells by culturing the stem cells in a differentiation medium containing ascorbic acid and hydrocortisone; producing a culture of stem cell-derived epidermal progenitor cells by culturing the differentiated stem cell-derived epidermal progenitor cells in a medium; and recovering the stem cell-derived epidermal progenitor cell conditioned medium from the culture of the stem cell-derived epidermal progenitor cells, a stem cell-derived epidermal progenitor cell conditioned medium prepared by the method, and a method of producing a protein from stem cell-derived epidermal progenitor cells, the method including the method of preparing the stem cell-derived epidermal progenitor cell conditioned medium.

The present invention discloses the preparation of placenta tissue derived CD106.sup.high CD151+Nestin+ mesenchymal stem cells (MSCs). In a first aspect, the invention relates to a particular method to prepare these cells at industrial scale and the cell population generated thereby. In a second aspect, the invention relates to a cell culture obtained by said particular method, containing placental CD106.sup.high CD151+Nestin+ MSCs expressing the vascular cell adhesion molecule 1 (VCAM-1) marker. The present application shows that said placental CD106.sup.high CD151+Nestin+ MSCs are capable of inducing angiogenesis in vitro and in vivo. The herein presented results also show that administering said placental CD106.sup.high CD151+Nestin+ MSCs to individuals suffering from an ischemic disease or from a disorder of the circulatory system results in a detectable improvement of one or more symptoms of said disease or disorder. Therefore, in a third aspect, the invention relates to placental CD 106.sup.high CD151+Nestin+ MSCs for use as a medicament for treating subjects suffering from an ischemic disease, a disorder of the circulatory system, an immune disease, an organ injury or an organ function failure.

Provided herein are isolated neural stem cells and methods of making neural stem cells from human trophoblast stem cells. The isolated neural stem cells can be immune privileged and express one or more protein(s). Also provided are methods for treatment of neurodegenerative diseases using suitable preparations comprising the isolated neural stem cells.

This disclosure is directed to methods for reproducibly generating substantial amounts of endothelial cells from non-vascular cells that display improved functionality and engraftability. The endothelial cells generated in accordance with the present methodology, as well as therapeutic methods utilizing these cells, are also disclosed.

Provided herein are isolated neural stem cells and methods of making neural stem cells from human trophoblast stem cells. The isolated neural stem cells can be immune-privileged and express one or more protein(s). Also provided are methods for treatment of neurodegenerative diseases using suitable preparations comprising the isolated neural stem cells.

The present invention relates to methods for deriving novel stem cells from the mammalian early neural plate.